Fig. 8. The combination of 6b with KLF5 inhibitor shows a better antitumor effect in the HCC1806 xenograft model.
A Gross morphology of HCC1806 xenograft tumors after mammary fat pad implantation with 6b (5 mg kg−1) or FZU-00,004 (50 mg kg−1) or combination (6b: 5 mg kg−1, FZU-00,004: 50 mg kg−1). DMSO serves as a negative control (n = 6). B 6b, FZU-00,004 or 6b+FZU inhibited tumor volumes, growth curves (mean ± SEM). C 6b, FZU-00,004 or 6b+FZU did not significantly change mouse body weights. D 6b, FZU-00,004, or 6b+FZU significantly decreased tumor weights. E. The mice were weighed at the end of the experiment. F, G The KLF5, BRD4 and Ki-67 levels were quantified by Image J after staining with specific antibodies in paraffin-embedded tissues, the scale bar equals 50 μM. The data are represented as means SD. n ≥ 6 for mice in each group. (*p < 0.05, **p < 0.01. ***p < 0.001. t-test).